A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (CO-338-017)
Johns Hopkins Kimmel Cancer Center in Baltimore
- To determine the efficacy of Rucaparib - To evaluate progression free survival
- Recurrent platinum sensitive ovarian, fallopian tube or primary peritoneal cancer - Platinum sensitive disease is defined as progression greater than 6 months after last dose of platinum agent - must have a biopsy prior to starting on study - measurable disease - Good lab results and performace status
Treatment is with an oral drug (Rucaparib) that is taken twice a day. It is given on an outpatient basis. You will be given a 28 day supply. There are additional lab and scan requirements.
05/30/2016 05:03 AM